Background & Aims: Infliximab induces immune cell apoptosis by outside-to-inside signaling through transmembrane tumor necrosis factor-alpha (mTNF). However, in inflamed gut, myofibroblasts also produce TNF-alpha, and the affects of anti-TNF antibodies on these structural cells are unknown. We investigated the action of infliximab on apoptosis, the production of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMP)-1, and migration of Crohn's disease (CD) myofibroblasts. Methods: Colonic myofibroblasts were isolated from patients with active CD and controls. mTNF was evaluated by Western blotting and flow cytometry. infliximab-treated myofibroblasts were analyzed for apoptosis by Annexin V staining and caspase-3. TIMP-1 and MMPs were measured by Western blotting, and fibroblast migration was assessed by using an in vitro wound-healing scratch assay. Results: CD myofibroblasts showed higher mTNF expression than control myofibroblasts. Infliximab had no effect on CD myofibroblast apoptosis, caspase-3 activation, and production of MMP-3 and MMP-12. However, infliximab induced a significant dose-dependent increase in TIMP-1 production, which was inhibited by the p38 mitogen-activated protein kinase inhibitor SB 203580. The anti-TNF agents adalimumab, etanercept, and p55 TNF-receptor-human IgG fusion protein also increased TIMP-1 production. The migration of CD myofibroblasts was enhanced significantly by infliximab and recombinant human TIMP-1, and infliximab-induced migration was inhibited by and-TIMP-1 neutralizing antibody. Infliximab also decreased CD myofibroblast collagen production. Conclusions: Our findings show a novel therapeutic pathway for anti-TNF therapies in enhancing TIMP-1 production and myofibroblast migration, which may reduce MMP activity and facilitate the wound healing.

Di Sabatino, A., Pender, S., Jackson, C.l., Prothero, J.d., Gordon, J.n., Picariello, L., et al. (2007). Functional modulation of crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. GASTROENTEROLOGY, 133(1), 137-149 [10.1053/j.gastro.2007.04.069].

Functional modulation of crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies

MONTELEONE, GIOVANNI;
2007-01-01

Abstract

Background & Aims: Infliximab induces immune cell apoptosis by outside-to-inside signaling through transmembrane tumor necrosis factor-alpha (mTNF). However, in inflamed gut, myofibroblasts also produce TNF-alpha, and the affects of anti-TNF antibodies on these structural cells are unknown. We investigated the action of infliximab on apoptosis, the production of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMP)-1, and migration of Crohn's disease (CD) myofibroblasts. Methods: Colonic myofibroblasts were isolated from patients with active CD and controls. mTNF was evaluated by Western blotting and flow cytometry. infliximab-treated myofibroblasts were analyzed for apoptosis by Annexin V staining and caspase-3. TIMP-1 and MMPs were measured by Western blotting, and fibroblast migration was assessed by using an in vitro wound-healing scratch assay. Results: CD myofibroblasts showed higher mTNF expression than control myofibroblasts. Infliximab had no effect on CD myofibroblast apoptosis, caspase-3 activation, and production of MMP-3 and MMP-12. However, infliximab induced a significant dose-dependent increase in TIMP-1 production, which was inhibited by the p38 mitogen-activated protein kinase inhibitor SB 203580. The anti-TNF agents adalimumab, etanercept, and p55 TNF-receptor-human IgG fusion protein also increased TIMP-1 production. The migration of CD myofibroblasts was enhanced significantly by infliximab and recombinant human TIMP-1, and infliximab-induced migration was inhibited by and-TIMP-1 neutralizing antibody. Infliximab also decreased CD myofibroblast collagen production. Conclusions: Our findings show a novel therapeutic pathway for anti-TNF therapies in enhancing TIMP-1 production and myofibroblast migration, which may reduce MMP activity and facilitate the wound healing.
2007
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/12 - GASTROENTEROLOGIA
English
4 (4 fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl)imidazole; adalimumab; caspase 3; collagen; etanercept; hybrid protein; infliximab; lipocortin 5; macrophage elastase; neutralizing antibody; p55 tumor necrosis factor receptor human igg fusion protein; stromelysin; tissue inhibitor of metalloproteinase 1; tissue inhibitor of metalloproteinase 1 neutralizing antibody; tumor necrosis factor antibody; adult; aged; apoptosis; article; assay; cell migration; clinical article; controlled study; Crohn disease; enzyme activation; enzyme synthesis; fibroblast; flow cytometry; human; human cell; human tissue; in vitro study; myofibroblast; priority journal; staining; Western blotting; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Apoptosis; Autoantibodies; Biopsy; Cells, Cultured; Collagen; Colon; Crohn Disease; Fibroblasts; Humans; Matrix Metalloproteinase 12; Matrix Metalloproteinase 3; Middle Aged; Organ Culture Techniques; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha; Wound Healing
Di Sabatino, A., Pender, S., Jackson, C.l., Prothero, J.d., Gordon, J.n., Picariello, L., et al. (2007). Functional modulation of crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. GASTROENTEROLOGY, 133(1), 137-149 [10.1053/j.gastro.2007.04.069].
Di Sabatino, A; Pender, Slf; Jackson, Cl; Prothero, Jd; Gordon, Jn; Picariello, L; Rovedatti, L; Docena, G; Monteleone, G; Rampton, Ds; Tonelli, F; Corazza, Gr; Macdonald, Tt
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/39343
Citazioni
  • ???jsp.display-item.citation.pmc??? 40
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 144
social impact